AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business UpdateBusiness Wire • 11/08/22
AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy SummitBusiness Wire • 11/07/22
AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher DiseaseBusiness Wire • 10/27/22
AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for CystinosisBusiness Wire • 10/25/22
AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher DiseaseBusiness Wire • 10/18/22
AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical DevelopmentBusiness Wire • 10/11/22
AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual CongressBusiness Wire • 09/27/22
AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for CystinosisBusiness Wire • 09/20/22
AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy TrialBusiness Wire • 09/14/22
AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business UpdateBusiness Wire • 08/09/22
AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter SyndromeBusiness Wire • 07/13/22
AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual MeetingBusiness Wire • 05/18/22
AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive MeasuresBusiness Wire • 05/17/22
AVROBIO Reports First Quarter 2022 Financial Results and Provides Business UpdateBusiness Wire • 05/10/22
AVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual MeetingBusiness Wire • 05/03/22
AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business UpdateBusiness Wire • 03/17/22
